TCDA - Tricida, Inc.

Tricida, Inc.

7000 Shoreline Court
Suite 201
South San Francisco, CA 94080
United States
415-429-7800
http://www.tricida.com

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 104

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Gerrit Klaerner	Founder, Pres, CEO & Exec. Director	814.08k	N/A	1971
Mr. Geoffrey M. Parker	CFO & Sr. VP	574.16k	N/A	1965
Dr. Dawn Parsell Ph.D.	Sr. VP of Clinical Devel.	486.23k	N/A	1962
Mr. Steffen Pietzke	VP of Fin. & Chief Accounting Officer	N/A	N/A	1972
Dr. Wilhelm Stahl	CTO & Sr. VP	N/A	N/A	1960

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Tricida, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.